Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago. The drugmaker also said Wednesday that it will ...
Biogen slashed the price of its controversial Alzheimer’s drug Aduhelm after a problematic rollout, but the move has still done little to encourage Medicare to cover the controversial drug. CMS is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback